BMS and Clovis Collaborate to Test Opdivo, Rubraca Combo Therapy in Ovarian, Other Cancer Types

BMS and Clovis Collaborate to Test Opdivo, Rubraca Combo Therapy in Ovarian, Other Cancer Types
A new clinical collaboration has been established between Bristol-Myers Squibb (BMS) and Clovis Oncology to evaluate the performance of Opdivo (nivolumab) in combination with Rubraca (rucaparib) in a Phase 3 trial for advanced ovarian cancer. Additional clinical trials testing the combination therapy will include patients with triple-negative breast cancer and metastatic prostate cancer. The pivotal Phase 3 trial will evaluate three lines of treatment as first-line maintenance therapy in patients with stage 3/4 high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy. Specifically, researchers will evaluate the action of Rubraca and Opdivo each delivered as a monotherapy, and as a combination of both drugs. The study will also include a control group, where patients will be given a placebo. Opdivo is an immunotherapy drug that binds and blocks the PD-1 protein, expressed at the surface of key cells of our immune system. Activating PD-1 through its binding partner, PD-L1, works as a type of “off switch,” shutting down immune cells. Antibodies targeting PD-1 or PD-L1, such as Opdivo, boost the immune response against cancer cells. Rubraca is a small molecule inhibitor of PARP enzymes, making it difficult for tumor cells to repair its DNA, a key step in their survival. Preclinical studies have also suggested that PARP inhibition impacts the immune system’s response against tumors, as shown by an increase of infiltrating T-cells into tumors. These results suggest that PARP inhibition and PD-1 blockade could potentially work in synergy
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *